Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 12, 2007, Pages 4410-4419

  Duraffour, Sophie ^a,b   Snoeck, Robert ^a   Krečmerová, Marcela ^c   Van Den Oord, Joost ^d   De Vos, Rita ^d   Holý, Antonín ^c   Crance, Jean Marc ^b   Garin, Daniel ^b   De Clercq, Erik ^a   Andrei, Graciela ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b CENTRE DE RECHERCHES   (France)

^c INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY   (Czech Republic)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]CYTOSINE; 2,4 DIAMINO 6 [2 (PHOSPHONOMETHOXY)ETHOXY]PYRIMIDINE; 5 BROMO 2,4 DIAMINO 6 [2 (PHOSPHONOMETHOXY)ETHOXY]PYRIMIDINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 CHLOROPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2 AMINO 6 METHYLPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 2,6 DIAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL] 6 DIMETHYLAMINOPURINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]ADENINE; 9 [2 (PHOSPHONOMETHOXY)ETHYL]GUANINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 2,6 DIAMINOPURINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL] 3 DEAZAADENINE; 9 [3 HYDROXY 2 (PHOSPHONOMETHOXY)PROPYL]ADENINE; [2,4 DIAMINO 3 HYDROXY 6 [2 (PHOSPHONOMETHOXY)PROPOXY]PYRIMIDINE; ACYCLIC NUCLEOSIDE; CIDOFOVIR; ESTER DERIVATIVE; N 2 [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]AMINOETHANE PHOSPHONIC ACID; N 2 [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]AMINOETHOXYMETHANEPHOSPHONIC ACID; N 2 [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]AMINOETHYLSULFONIC ACID; N [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]AMINOMETHYLSULFONIC ACID; N [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]ASPARTIC ACID; N [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]IMINODEIACETIC ACID; N [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]LEUCINE; N [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]PHENYLALANINE; N [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]SERINE; N [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]THREONINE; N [3 [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]AMINO]PROPANOIC ACID; N [4 [2 AMINO 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURIN 6 YL]AMINO]BUTANOIC ACID; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CAMELPOX VIRUS; CYTOPATHOGENIC EFFECT; DRUG SYNTHESIS; EMBRYO; HISTOLOGY; HUMAN; HUMAN CELL; KERATINOCYTE; MODEL; MONOLAYER CULTURE; NEWBORN; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; SKIN EPITHELIUM; TISSUE CULTURE; VIRUS REPLICATION; VIRUS STRAIN;

ADENINE; ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELLS, CULTURED; CYTOSINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INFANT, NEWBORN; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NUCLEOSIDES; ORGANOPHOSPHORUS COMPOUNDS; ORTHOPOXVIRUS; PHOSPHONIC ACIDS; SWISS 3T3 CELLS; VIRUS REPLICATION;

EID: 36749040780     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00838-07     Document Type: Article

References (44)

1. Andrei, G. 2006. Three-dimensional culture models for human viral diseases and antiviral drug development. Antivir. Res. 71:96-107.
2. Andrei, G., M. Krecmerová, A. Holý, L. Naesens, J. Neyts, J. Balzarini, E. De Clercq, and R. Snoeck. 2007. In vivo antiviral activity of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine and its cyclic form. Antivir. Res. 74:A-17.
3. Azwai, S. M., S. D. Carter, Z. Woldehiwet, and U. Wernery. 1996. Serology of Orthopoxvirus cameli infection in dromedary camels: analysis by ELISA and Western blotting. Comp. Immunol. Microbiol. Infect. Dis. 19:65-78.
4. Balzarini, J., C. Pannecouque, L. Naesens, G. Andrei, R. Snoeck, E. De Clercq, D. Hockovä, and A. Holý. 2004. 6-[2-(Phosphonomethoxy) alkoxy]-2,4-diaminopyrimidines: a new class of acyclic pyrimidine nucleoside phosphonates with antiviral activity. Nucleosides Nucleotides Nucleic Acids 23:1321-1327.
5. Baxby, D. 1974. Differentiation of smallpox and camelpox viruses in cultures of human and monkey cells. J. Hyg. (London) 72:251-254.
6. Behbehani, A. M. 1983. The smallpox story: life and death of an old disease. Microbiol. Rev. 47:455-509.
7. Bonatti, H., F. Aigner, E. De Clercq, C. Boesmueller, A. Widschwendner, C. Larcher, R. Margreiter, and S. Schneeberger. 2007. Local administration of cidofovir for human papilloma virus associated skin lesions in transplant recipients. Transpl. Int. 20:238-246.
8. Bray, M., M. Martinez, D. F. Smee, D. Kefauver, E. Thompson, and J. W. Huggins. 2000. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge. J. Infect. Dis. 181:10-19.
9. Centers for Disease Control and Prevention. 2003. Smallpox Vaccine Adverse Events Monitoring and Response System for the first stage of the sihallpox vaccination program. Morb. Mortal. Wkly. Rep. 52:88-89, 99.
10. Ciesla, S. L., J. Trahan, W. B. Wan, J. R. Beadle, K. A. Aldern, G. R. Painter, and K. Y. Hostetler. 2003. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney. Antivir. Res. 59:163-171.
11. Cundy, K. C., J. A. Fishback, J. P. Shaw, M. L. Lee, K. F. Soike, G. C. Visor, and W. A. Lee. 1994. Oral bioavailability of the antiretroviral agent 9-(2-phosphonylmethoxyethyl)adenine (PMEA) from three formulations of the prodrug bis(pivaloyloxymethyl)-PMEA in fasted male cynomolgus monkeys. Pharm. Res. 11:839-843.
12. Dal Pozzo, F., G. Andrei, A. Holý, J. Van Den Oord, A. Scagliarini, E. De Clercq, and R. Snoeck. 2005. Activities of acyclic nucleoside phosphonates against orf virus in human and ovine cell monolayers and organotypic ovine raft cultures. Antimicrob. Agents Chemother. 49:4843-4852.
13. De Clercq, E. 2002. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 55:1-13.
14. De Clercq, E. 2003. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 16:569-596.
15. De Clercq, E. 2007. Acyclic nucleoside phosphonates: past, present and future. Bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge. Biochem. Pharmacol. 73:911-922.
16. De Clercq, E., G. Andrei, J. Balzarini, P. Leyssen, L. Naesens, J. Neyts, C. Pannecouque, R. Snoeck, C. Ying, D. Hocková, and A. Holý. 2005. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4- diaminopyrimidines. Nucleosides Nucleotides Nucleic Acids 24:331-341.
17. Delhon, G., E. R. Tulman, C. L. Afonso, Z. Lu, A. Concha-Bermejillo, H. D. Lehmkuhl, M. E. Piccone, G. F. Kutish, and D. L. Rock. 2004. Genomes of the parapoxviruses orf virus and bovine papular stomatitis virus. J. Virol. 78:168-177.
18. Di Giulio, D. B., and P. B. Eckburg. 2004. Human monkeypox: an emerging zoonosis. Lancet Infect. Dis. 4:15-25.
19. Duraffour, S., R. Snoeck, R. De Vos, J. Van Den Oord, J. M. Crance, D. Garin, D. Hruby, R. Jordan, E. De Clercq, and G. Andrei. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia virus, cowpox virus and camelpox virus in primary human keratinocyte monolayers and organotypic raft cultures. Antivir. Ther., in press.
20. Fenner, F. 1989. Risks and benefits of vaccinia vaccine use in the worldwide smallpox eradication campaign. Res. Virol. 140:465-466.
21. Geerinck, K., G. Lukito, R. Snoeck, R. De Vos, E. De Clercq, Y. Vanrenterghem, H. Degreef, and B. Maes. 2001. A case of human orf in an immunocompromised patient treated successfully with cidofovir cream. J. Med. Virol. 64:543-549.
22. Gitao, C. G. 1997. An investigation of camelpox outbreaks in two principal camel (Camelus dromedarius) rearing areas of Kenya. Rev. Sci. Tech. 16:841-847.
23. Gubser, C., and G. L. Smith. 2002. The sequence of camelpox virus shows it is most closely related to variola virus, the cause of smallpox. J. Gen. Virol. 83:855-872.
24. Hocková, D., A. Holý, M. Masojídková, G. Andrei, R. Snoeck, E. De Clercq, and J. Balzarini. 2004. Synthesis and antiviral activity of 2,4-diamino-5-cyano-6-[2-(phosphonomethoxy)ethoxy] pyrimidine and related compounds. Bioorg. Med. Chem. 12:3197-3202.
25. Huggins, J. W., D. Smee, M. J. Martinez, and M. Bray. 1998. Cidofovir (HPMPC) treatment of monkeypox. Antivir. Res. 37:A-73.
26. Jezek, Z., B. Kriz, and V. Rothbauer. 1983. Camelpox and its risk to the human population. J. Hyg. Epidemiol. Microbiol. Immunol. 27:29-42.
27. Kinne, J., J. E. Cooper, and U. Wernery. 1998. Pathological studies on camelpox lesions of the respiratory system in the United Arab Emirates (UAE). J. Comp. Pathol. 118:257-266.
28. Krecmerová, M., A. Holý, A. Pískala, M. Masojídková, G. Andrei, L. Naesens, J. Neyts, J. Balzarini, E. De Clercq, and R. Snoeck. 2007. Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds. J. Med. Chem. 50:1069-1077.
29. Lebeau, I., G. Andrei, F. Dal Pozzo, J. R. Beadle, K. Y. Hostetler, E. De Clercq, J. Van Den Oord, and R. Snoeck. 2006. Activities of alkoxyalkyl esters of cidofovir (CDV), cyclic CDV, and (S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine against orthopoxviruses in cell monolayers and in organotypic cultures. Antimicrob. Agents Chemother. 50:2525-2529.
30. Lebeau, I., G. Andrei, M. Krecmerová, E. De Clercq, A. Holý, and R. Snoeck. 2007. Inhibitory activity of three classes of acyclic nucleoside phosphonates against murine Polyomavirus and primate SV40 strains. Antimicrob. Agents Chemother. 51:2268-2273.
31. Marris, E. 2007. Dramatic rescue relieves rare case of smallpox infection. Nat. Med. 13:517.
32. Pfeffer, M., H. Meyer, U. Wernery, and O. R. Kaaden. 1996. Comparison of camelpox viruses isolated in Dubai. Vet. Microbiol. 49:135-146.
33. Ramyar, H., and M. Hessami. 1972. Isolation, cultivation and characterization of camel pox virus. Zentbl. Veterinarmed. B 19:182-189.
34. Shaw, J. P., M. S. Louie, V. V. Krishnamurthy, M. N. Arimilli, R. J. Jones, A. M. Bidgood, W. A. Lee, and K. C. Cundy. 1997. Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. Drug Metab. Dispos. 25:362-366.
35. Shaw, J. P., C. M. Sueoko, R. Oliyai, W. A. Lee, M. N. Arimilli, C. U. Kim, and K. C. Cundy. 1997. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharm. Res. 14:1824-1829.
36. Smee, D. F., K. W. Bailey, and R. W. Sidwell. 2001. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir. Chem. Chemother. 12:71-76.
37. Smee, D. F., R. W. Sidwell, D. Kefauver, M. Bray, and J. W. Huggins. 2002. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 46:1329-1335.
38. Smee, D. F., M. H. Wong, K. W. Bailey, J. R. Beadle, K. Y. Hostetler, and R. W. Sidwell. 2004. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int. J. Antimicrob. Agents 23:430-437.
39. Snoeck, R., G. Andrei, and E. De Clercq. 2007. Therapy of poxvirus infections, p. 375-395. In A. A. Mercer, A. Schmidt, and O. Weber (ed.), Poxviruses. Birkhäuser, Basel, Switzerland.
40. Snoeck, R., C. Dewolf-Peeters, J. Van Den Oord, E. D. Clereq, and G. Andrei. 2002. Antivaccinia activities of acyclic nucleoside phosphonate derivatives in epithelial cells and organotypic cultures. Antimicrob. Agents Chemother. 46:3356-3361.
41. Starrett, J. E., Jr., D. R. Tortolani, M. J. Hitchcock, J. C. Martin, and M. M. Mansuri. 1992. Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Antivir. Res. 19:267-273.
42. Stittelaar, K. J., J. Neyts, L. Naesens, G. van Amerongen, R. F. van Lavieren, A. Holý, E. De Clercq, H. G. Niesters, E. Fries, C. Maas, P. G. Mulder, B. A. van der Zeijst, and A. D. Osterhaus. 2006. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection. Nature 439:745-748.
43. Wernery, U., and O. R. Kaaden. 2002. Infectious diseases in camelids, 2nd ed., p. 176-187. Blackwell Science, Berlin, Germany.
44. Wernery, U., and R. Zachariah. 1999. Experimental camelpox infection in vaccinated and unvaccinated dromedaries. Zentbl. Veterinarmed. B 46:131-135.